This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements as further described in the “Risk Factors” section of the information statement contained in the 10K and other filings made by Chemours with the Securities and Exchange Commission. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA, which should not be considered as replacements of GAAP. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com.
The Chemours Company at a Glance

2015 Sales: $5,717
2015 Adj. EBITDA: $573
% margin: 10%

Titanium Technologies
Sales: $2,392
Adj. EBITDA: 326
% margin: 14%

- Titanium dioxide (TiO₂) is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight
- #1 global producer of TiO₂ by capacity, sales and profitability

Fluoroproducts
Sales: $2,230
Adj. EBITDA: 300
% margin: 13%

- Products for high performance applications across broad array of industries, including refrigerants, propellants and industrial resins
- #1 global producer of both fluorochemicals and fluoropolymers

Chemical Solutions
Sales: $1,095
Adj. EBITDA: 29
% margin: 3%

- Chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries
- #1 producer in Americas sodium cyanide
- #1 in US Northeast sulfuric acid regeneration
- #2 in US Gulf Coast sulfuric acid regeneration

By Geography
- North America 45%
- Asia Pacific 24%
- EMEA 17%
- Latin America 14%

By Product
- Titanium Dioxide 42%
- Fluoropolymers 22%
- Fluorochemicals 17%
- Performance Chemicals & Intermediates 9%
- Cyanides 6%
- Sulfur Products 4%
- Other 6%

Dollars in millions. Data represents twelve months ending December 31, 2015. Adjusted EBITDA includes corporate and other charges which are not reflected in individual segment Adjusted EBITDA. Geographic and product data reflect full year 2015 sales. See reconciliation of Adjusted EBITDA in Appendix.
Business Overview

- **Global leader in TiO₂ with production capacity of 1.2 million metric tons**
  - 4 TiO₂ plants with 7 production lines
  - Packaging facility at Kallo, Belgium
  - Mineral sands mine at Starke, FL
- **Industry-leading manufacturing cost position**
  - Unique chloride technology
  - Feedstock flexibility
- **Strong brand reputation**
  - Ti-Pure® sold to ~800 customers globally

Chemours is #1 in TiO₂ Globally

- Coatings – architectural, industrial, automotive
- Plastics – rigid / flexible packaging, PVC pipe/windows
- Papers – laminate papers, coated paper/paperboard, sheet

Source: Company filings and data. Titanium Technologies: TZMI (2014)

(1) Pro forma for completion of Altamira expansion in mid-2016
(2) TiO₂ market share statistics based on production per 2014 TZMI
(3) Pro forma for Rockwood acquisition (Sachtleben)
(4) Reflects full year 2015 segment net sales
Supplies products for high performance applications across broad array of industries

- #1 in Fluoroproducts globally
  - Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents
  - Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties

Key Brands include Teflon®, Freon®, Opteon®, Viton®

Fluoroproducts Business Overview

- Fluorochemicals – mainly refrigerants, propellants, and foam expansion agent
- Fluoropolymers – mainly industrial resins and downstream products & coatings
- Key End Markets – AC, refrigeration, automotive, aerospace, consumer, wire & cable, electronics and telecommunications

Source: Company filings and data, Fluoroproducts: Company filings and Management estimates
(1)Reflects full year 2015 segment net sales
(2)Fluorochemicals and fluoropolymers market share statistics based on 2014 internal revenue estimates and company filings
(3)Includes 100% contribution from the DuPont-Mitsui Fluorocarbon Company joint venture
Business Overview

- Diverse portfolio of industrial businesses primarily operating in the Americas
- Unmatched reputation for safety, reliability and stewardship
- 14 production facilities located in North America and one located in the U.K.

Cyanide Competitive Advantages

- Market leadership
- Favorable end market dynamics
- Selective, high-return investment opportunity

Chemical Solutions Overview

**Geography**

- North America: 70%
- Latin America: 17%
- EMEA: 4%
- Asia Pacific: 9%

**Product**

- Cyanides: 29%
- Sulfur: 23%
- Performance Chemicals & Intermediates: 48%

Source: Company filings and data

(1) Reflects full year 2015 segment net sales

**Cyanides** – sodium cyanide, hydrogen cyanide, potassium cyanide

**Sulfur Products** – non-fuming sulfuric acid, spent acid regeneration, sulfur derivatives

**Performance Chemicals and Intermediates** – aniline, methylamines, reactive metals, clean and disinfect chemicals
## Transformation Plan Priorities

### Reduce Costs
- Achieved cost reductions of ~$100M in second half of 2015
- Additional cost reduction target of $350M through 2017 over 2015

### Optimize The Portfolio
- Signed definitive agreement to sell Aniline facility
- Evaluating strategic alternatives for all other assets in the Chemical Solutions portfolio
- Retaining and improving cost position of Methylamines business
- Investing in Cyanides business

### Grow Market Positions
- Support customer growth in TiO₂ through successful Altamira start-up
- Continue ramp up of Opteon™ product line in Fluoroproducts
- Grow Cyanides business with key customers
- Target $150M Adjusted EBITDA growth from Opteon™, Altamira, and Cyanides through 2017

### Refocus Investments
- Concentrate capital spending on investable business portfolio
- Invest in the next increment of Opteon™ capacity
- Rationalize annual capital spending to ~$350M in 2017

### Enhance Our Organization
- Foster an entrepreneurial organization
- Operate with a simpler structure
- Maintain a commitment to a safe and sustainable future

---

Plan Well Underway to Enhance Adjusted EBITDA and Improve Cash Flow
Progress on Transformation Plan

### Cost Reduction Progress

- **$350M Incremental to 2015**
- **$300M**
- **$100M**

#### 2H2015
- Pension
- 3Q15 Capacity Shutdowns

#### 2016
- Procurement & Productivity
- 4Q15 Restructuring & Employee Related

#### 2017
- Remaining Target
- RMS Shutdown
- 2Q Restructuring & Employee-Related

---

### Other Transformation Activity

#### Portfolio Optimization
- Announced sale of Aniline facility
- Beginning shutdown process for Niagara RMS site
- Implementing improvement plan for Methylamines business
- Evaluating Sulfur and Clean & Disinfect

#### Growing Market Positions
- Opteon™ expected to ramp up in 2016
- Mechanical completion of Altamira TiO₂ facility
- On track for cyanides expansion

#### Refocusing Investments
- Reduce capex by ~$100M from 2015, on path to ~$350M in 2017
- Evaluation for next tranche of Opteon™ capacity underway
### Full Year Financial Summary

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>Δ Yr/Yr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales</td>
<td>$5,717</td>
<td>$6,432</td>
<td>($716)</td>
</tr>
<tr>
<td>Adj. EBITDA</td>
<td>573</td>
<td>876</td>
<td>(303)</td>
</tr>
<tr>
<td><strong>Adj. EBITDA Margin (%)</strong></td>
<td>10.0</td>
<td>13.6</td>
<td>(3.6)</td>
</tr>
<tr>
<td>Net Income</td>
<td>(90)</td>
<td>400</td>
<td>(490)</td>
</tr>
<tr>
<td>Adj. Net Income</td>
<td>143</td>
<td>453</td>
<td>(310)</td>
</tr>
<tr>
<td>EPS¹</td>
<td>($0.50)</td>
<td>$2.21</td>
<td>($2.71)</td>
</tr>
<tr>
<td>Adj. EPS¹</td>
<td>$0.79</td>
<td>$2.50</td>
<td>($1.71)</td>
</tr>
<tr>
<td>Free Cash Flow²</td>
<td>(337)</td>
<td>(99)</td>
<td>(238)</td>
</tr>
</tbody>
</table>

- Double-digit Adjusted EBITDA margin despite currency headwinds and continued TiO₂ pricing pressures
- Cost reductions of ~$100M in the second half
  - ~$60M lower SG&A³ and R&D
  - ~$40M lower COGS
- Working capital programs initiated to achieve long term productivity benefits
- Mechanical completion of Altamira

See reconciliation of Non-GAAP measures in the Appendix

1 Periods prior to 3Q15 are represented by pro forma basic and diluted EPS
2 Defined as Cash from Operations minus cash used for PP&E purchases
3 Reflects exclusions to Adjusted EBITDA
Adjusted EBITDA Bridge: 2015 versus 2014

($ in millions)

2014

- Currency: $876
- Local Price: ($223)
- Volume: ($337)
- Cost: $302
- Other: $2
- Total: $573

2015

- TiO₂ price down 12%
- Lower prices in Chemical Solutions
- Reduced fluoropolymer demand
- Lower quota volumes of refrigerants
- Lower TiO₂ volume
- Lower controllable costs
- Lower stand alone costs
- Reduced raw material pricing
- Technology and licensing activity

See reconciliation of Non-GAAP measures in the Appendix
Liquidity Position

($ in millions)

2Q15 Cash Balance: $247
2H15 Net Income (Loss): ($115)
Depr., Amort. Impairment: $342
Deferred Tax & Other: ($159)
Working Capital: $347
CAPEX: ($232)
Dividend: ($105)
Other: $41
4Q15 Cash Balance: $366

2H15 Operating Cash Flow $415M
• **Enhanced liquidity from agreement with DuPont**
  – Extinguished cash and working capital true-ups contemplated in Separation Agreement with no payments
  – DuPont prepaid Chemours ~$190M for goods and services anticipated over the next 12 – 15 months

• **Additional flexibility from amendment of financial maintenance covenants in the revolving credit facility completed on February 19**
  – Changed leverage covenant to be calculated only on senior secured net debt basis, maximum cash offset of $400M to debt
  – Adjusted interest coverage ratio levels
  – Modified definition of Consolidated EBITDA to increase pro forma EBITDA add-backs for cost savings actions:
    • $125M through June 30, 2017
    • $80M through June 30, 2018
  – Deadline for permitted cost savings actions extended to June 30, 2017
  – Reduced revolver commitment by $250M; $750M total facility
Net Working Capital and Other Operating Activities

Seasonality of Titanium Technologies and Fluoroproducts Segments Drives Working Capital and Cash Usage
Covenant Ratios

Total Net Leverage Ratio: replaced with Senior Secured Net Leverage Ratio\(^1\) covenant, set at levels in table below:

Interest Expense Coverage Ratio: amended applicable ratios to the levels set in the table below:

<table>
<thead>
<tr>
<th>Period</th>
<th>Senior Secured Net Leverage Ratio</th>
<th>Interest Expense Coverage Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Through 12/31/2016</td>
<td>3.50x</td>
<td>1.75x</td>
</tr>
<tr>
<td>01/01/17 through 6/30/2017</td>
<td>3.00x</td>
<td>1.75x</td>
</tr>
<tr>
<td>07/01/2017 through 12/31/2017</td>
<td>2.75x</td>
<td>2.00x</td>
</tr>
<tr>
<td>01/01/2018 through 6/30/2018</td>
<td>2.50x</td>
<td>2.25x</td>
</tr>
<tr>
<td>07/01/2018 through 12/31/2018</td>
<td>2.25x</td>
<td>2.50x</td>
</tr>
<tr>
<td>01/01/2019 and thereafter</td>
<td>2.00x</td>
<td>3.00x</td>
</tr>
</tbody>
</table>

\(^1\) Based on Credit Agreement defined LTM Adjusted EBITDA, as amended February 2016, including pro forma adjustments, Senior Secured Net Debt/EBITDA of 1.5x
2016 Outlook

- Full-year Adjusted EBITDA expected to be greater than 2015 level
- Reaffirm $200M in cost reduction target from transformation plan
- Full-year free cash flow anticipated to be modestly positive

Key Factors Influencing 2016 Performance:

**Market Factors**
- TiO$_2$ price
- Currency
- End-market demand

**Chemours Initiatives**
- Cost reductions
- Working capital productivity
- Ramp up in Opteon™
- Altamira start-up

2016 Adjusted EBITDA Expected to be greater than 2015 with Modestly Positive Free Cash Flow
Appendix
GAAP Net (Loss) Income to Adjusted EBITDA and Adjusted Net Income Reconciliations

($ in millions unless otherwise noted)

<table>
<thead>
<tr>
<th>Net (loss) income attributable Chemours</th>
<th>Three months ended</th>
<th>Year ended December 31,</th>
<th>Three months ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>December 31,</td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(86)</td>
<td>79</td>
</tr>
<tr>
<td>Non-operating pension and other postretirement employee benefit costs</td>
<td></td>
<td>(8)</td>
<td>4</td>
</tr>
<tr>
<td>Exchange losses (gains)</td>
<td></td>
<td>28</td>
<td>37</td>
</tr>
<tr>
<td>Restructuring charges</td>
<td></td>
<td>85</td>
<td>-</td>
</tr>
<tr>
<td>Asset impairments</td>
<td></td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Losses (gains) on sale of business or assets</td>
<td></td>
<td>9</td>
<td>(28)</td>
</tr>
<tr>
<td>Transaction, legal and other charges</td>
<td></td>
<td>17</td>
<td>-</td>
</tr>
<tr>
<td>Benefit from income taxes relating to reconciling items</td>
<td></td>
<td>(43)</td>
<td>(1)</td>
</tr>
<tr>
<td><strong>Adjusted Net Income</strong></td>
<td></td>
<td>5</td>
<td>91</td>
</tr>
<tr>
<td>Net income attributable to noncontrolling interests</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest expense</td>
<td></td>
<td>53</td>
<td>72</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td></td>
<td>66</td>
<td>72</td>
</tr>
<tr>
<td>All remaining provision for income taxes</td>
<td></td>
<td>8</td>
<td>42</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td></td>
<td>132</td>
<td>205</td>
</tr>
</tbody>
</table>

| Adjusted earnings per share, basic    |                    | $0.03 | $0.50 | $0.79 | $2.50 | $0.40 |
| Adjusted earnings per share, diluted  |                    | $0.03 | $0.50 | $0.79 | $2.50 | $0.40 |

1 Total of (benefit from) provision for income taxes reconciles to the amount reported in the statement of operations for the years ended December 31, 2015, 2014 and 2013.

2 On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours’ common stock to holders of its common stock. Basic and diluted (loss) earnings per common share for the three-months and year ended December 31, 2014 were calculated using the shares distributed on July 1, 2015.
<table>
<thead>
<tr>
<th></th>
<th>Three months ended December 31, 2015</th>
<th>Three months ended December 31, 2014</th>
<th>Year ended December 31, 2015</th>
<th>Three months ended September 30, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SEGMENT NET SALES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titanium Technologies</td>
<td>589</td>
<td>688</td>
<td>2,392</td>
<td>2,937</td>
</tr>
<tr>
<td>Fluoroproducts</td>
<td>515</td>
<td>575</td>
<td>2,230</td>
<td>2,327</td>
</tr>
<tr>
<td>Chemical Solutions</td>
<td>256</td>
<td>286</td>
<td>1,095</td>
<td>1,168</td>
</tr>
<tr>
<td><strong>Total Company</strong></td>
<td>1,360</td>
<td>1,549</td>
<td>5,717</td>
<td>6,432</td>
</tr>
<tr>
<td><strong>SEGMENT ADJUSTED EBITDA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titanium Technologies</td>
<td>62</td>
<td>160</td>
<td>326</td>
<td>723</td>
</tr>
<tr>
<td>Fluoroproducts</td>
<td>80</td>
<td>73</td>
<td>300</td>
<td>282</td>
</tr>
<tr>
<td>Chemical Solutions</td>
<td>16</td>
<td>1</td>
<td>29</td>
<td>17</td>
</tr>
<tr>
<td>Corporate &amp; Other</td>
<td>(26)</td>
<td>(29)</td>
<td>(82)</td>
<td>(146)</td>
</tr>
<tr>
<td><strong>Total Company</strong></td>
<td>132</td>
<td>205</td>
<td>573</td>
<td>876</td>
</tr>
<tr>
<td><strong>SEGMENT ADJUSTED EBITDA MARGIN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titanium Technologies</td>
<td>10.5%</td>
<td>23.3%</td>
<td>13.6%</td>
<td>24.6%</td>
</tr>
<tr>
<td>Fluoroproducts</td>
<td>15.5%</td>
<td>12.7%</td>
<td>13.5%</td>
<td>12.1%</td>
</tr>
<tr>
<td>Chemical Solutions</td>
<td>6.3%</td>
<td>0.3%</td>
<td>2.6%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Corporate &amp; Other</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td><strong>Total Company</strong></td>
<td>9.7%</td>
<td>13.2%</td>
<td>10.0%</td>
<td>13.6%</td>
</tr>
</tbody>
</table>

**NOTE:** In September 2015, the Company updated its definition of Adjusted EBITDA. All prior periods have been updated to reflect the current presentation.